Patents by Inventor Robert T. Chatterton

Robert T. Chatterton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4522831
    Abstract: Ovarian follicular development and related hormonal secretions are totally suppressed for periods of several months or longer by a single intramuscular injection of anordrin administered during menstruation given preferably on the first day of menstrual bleeding. The amount of anordrin administered is in the range of 2 to 10 mg per kg of body weight, and is effective to produce the suppression without administration of additional anordrin by any route. Suppression of progesterone and estradiol secretions is of therapeutic value in the treatment of endometrosis, breast cancer, and other conditions aggravated by ovarian hormones.
    Type: Grant
    Filed: May 2, 1983
    Date of Patent: June 11, 1985
    Assignee: Northwestern University
    Inventor: Robert T. Chatterton, Jr.
  • Patent number: 4450239
    Abstract: A method is provided for determining the concentration of pregnanediol glucuronide (PG) in a woman's urine which is characterized by utilization of the reagent 20.alpha.-hydroxy-4-pregnen-3-one (20-.alpha. reagent) in a form in which it reacts with antibodies binding to PG. The method is adaptable to a visual color indication test which can be performed by the woman herself as well as by laboratory analysis. The method can be used to define the period in which conception can occur, to define a post-ovulation safe period in which conception is prevented, and as an early pregnancy indicator.
    Type: Grant
    Filed: September 23, 1981
    Date of Patent: May 22, 1984
    Assignee: Northwestern University
    Inventor: Robert T. Chatterton
  • Patent number: RE32557
    Abstract: A method is provided for determining the concentration of pregnanediol glucuronide (PG) in a woman's urine which is characterized by utilization of the reagent 20.alpha.-hydroxy-4-pregnen-3-one (20-.alpha. reagent) in a form in which it reacts with antibodies binding to PG. The method is adaptable to a visual color indication test which can be performed by the woman herself as well as by laboratory analysis. The method can be used to define the period in which conception can occur, to define a post-ovulation safe period in which conception is prevented, and as an early pregnancy indicator.
    Type: Grant
    Filed: February 27, 1986
    Date of Patent: December 8, 1987
    Assignee: Northwestern University
    Inventor: Robert T. Chatterton